CVE:RVV Revive Therapeutics (RVV) Stock Price, News & Analysis → VIPs Only (Do NOT Share This) (From Profits Run) (Ad) Free RVV Stock Alerts C$0.08 +0.01 (+14.29%) (As of 07/22/2019) Add Compare Share Share Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.0852-Week RangeC$0.07▼C$0.25Volume212,852 shsAverage Volume93,085 shsMarket CapitalizationC$5.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Revive Therapeutics alerts: Email Address Ad Behind the MarketsMemorial Day Sale! Get 90% OFF Behind the Markets!Today, I'm offering you the chance to receive a PLATINUM BTM subscription for up to 90% OFF! If you want to see just how much your mystery discount is...You can UNCOVER YOUR MYSTERY DISCOUNT HERE! About Revive Therapeutics Stock (CVE:RVV)Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.Read More RVV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVV Stock News HeadlinesApril 23, 2024 | tmcnet.comRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDApril 18, 2024 | markets.businessinsider.comRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductMarch 27, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 27, 2024 | finance.yahoo.comRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 19, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 19, 2024 | markets.businessinsider.comRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 12, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate UpdateMarch 12, 2024 | financialpost.comRevive Therapeutics Provides Corporate UpdateFebruary 26, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110February 1, 2024 | markets.businessinsider.comRevive Therapeutics Explores the Use of Bucillamine for Long COVIDJanuary 31, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500January 24, 2024 | financialpost.comRevive Therapeutics Ltd. Announces Offering of Up to $3 MillionJanuary 16, 2024 | tmcnet.comRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaJanuary 10, 2024 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 10, 2024 | markets.businessinsider.comRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 8, 2024 | msn.comTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40MDecember 20, 2023 | markets.businessinsider.comRevive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersDecember 18, 2023 | markets.businessinsider.comRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of BucillamineDecember 18, 2023 | financialpost.comRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent ExposureOctober 11, 2023 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentOctober 11, 2023 | tmcnet.comRevive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentSeptember 28, 2023 | ft.comItaly turns to Kyrgyz shepherds to revive Sardinian farmingAugust 22, 2023 | finanznachrichten.deRevive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation DevelopmentSee More Headlines Receive RVV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/25/2024Next Earnings (Estimated)6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:RVV CUSIPN/A CIKN/A Webwww.revivethera.com Phone+1-905-6055535FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.14 Quick Ratio6.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow3.18 Book ValueC$0.02 per share Price / Book4.21Miscellaneous Outstanding Shares72,411,000Free FloatN/AMarket CapC$5.79 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Craig Leon (Age 51)Chairman & CEO Mr. Fabio Chianelli (Age 41)Pres & Director Mr. Carmelo Marrelli C.A. (Age 48)C.P.A., CPA, B.Comm., CA, CGA, ACIS, Chief Financial Officer Key CompetitorsQuest PharmaTechCVE:QPTInnovotechCVE:IOTHemostemixCVE:HEMPacgen Life Science Co. (PBS.V)CVE:PBSMedifocus Inc. (MFS.V)CVE:MFSView All CompetitorsInsidersMichael FrankBought 150,000 shares on 3/18/2024Total: C$5,250.00 ($0.04/share)Michael FrankBought 304,000 shares on 3/15/2024Total: C$9,120.00 ($0.03/share) RVV Stock Analysis - Frequently Asked Questions How have RVV shares performed in 2024? Revive Therapeutics' stock was trading at C$0.08 at the beginning of the year. Since then, RVV stock has increased by 0.0% and is now trading at C$0.08. View the best growth stocks for 2024 here. When is Revive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our RVV earnings forecast. What other stocks do shareholders of Revive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revive Therapeutics investors own include Heat Biologics (HTBX), Green Organic Dutchman (TGOD), Aurora Cannabis (ACB), CytoDyn (CYDY), Genprex (GNPX), iBio (IBIO), Sorrento Therapeutics (SRNE), Workhorse Group (WKHS), Acasti Pharma (ACST) and Anavex Life Sciences (AVXL). How do I buy shares of Revive Therapeutics? Shares of RVV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:RVV) was last updated on 5/25/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThis could mean the end of the U.S dollar…Colonial MetalsVIPs Only (Do NOT Share This)Profits RunDems have chosen Biden replacement?Paradigm Press[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyA personal note from Behind The Markets' CEO Dylan Jovine...Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.